OBIO Orchestra BioMed Holdings, Inc. Insider Trading

David P Hochman purchased 5,000 shares of OBIO at $3.83; stock now down 27.9% from 52-week high as company burns cash amid growth.

David P Hochman purchased 5,000 shares at $3.83, increasing his total holdings to 1.06M shares, a modest 0.5% addition to his existing position. His cross-ticker track record shows weak timing discipline (21.43% 90-day win rate with average 90d return of +3.6%), and at OBIO specifically, he has mixed results: 3 of 5 prior buys posted positive 90-day returns, but his most recent purchase on 2026-05-15 has yielded only 1.6% gain at the 90-day mark. The company context raises concerns: OBIO is unprofitable with $-20.7M net income in its most recent full fiscal year, revenue of only $110.0K in the latest quarter, and the stock is currently -27.9% from its 52-week high. While the substantial annual revenue growth of +1169.2% appears dramatic, this reflects a very early-stage company with minimal absolute revenue, and the timing of this purchase against current price weakness and ongoing losses warrants scrutiny of whether the insider possesses non-public information or is simply averaging into a distressed position.

Hochman buys 5,000 OBIO shares at $3.77; stock -26.2% from 52-week high, -12.7% in 30 days

David P Hochman purchased 5,000 shares at $3.77 on 2026-05-15, expanding his holdings to 1.06M shares, while OBIO trades -26.2% below its 52-week high of $5.42 and -12.7% over the past 30 days. Among his prior trades at OBIO, timing results are mixed: 2 of 5 prior buys delivered positive 90-day returns, while the most recent buy on 2026-03-13 at an earlier price point returned -3.7% in 30 days and -7.2% over 90 days, suggesting recent buying has not been consistently rewarded. The company faces material headwinds—it reported $110.0K in latest quarterly revenue against a $-20.7M net loss for the most recent full year, though annual revenue growth of +1169.2% indicates recent acceleration from a very small base. The current purchase near depressed price levels warrants monitoring of whether the insider perceives stabilization or whether further deterioration follows.

Director Aryeh Jason bought 8,971 shares of OBIO at $3.90 on 2026-05-15; prior buy at same ticker returned +77.1% in 90 days

Aryeh Jason, a Director at Orchestra BioMed Holdings (OBIO), purchased 8,971 shares at $3.90 on 2026-05-15 for $34,986.90, increasing his holdings by 8.3%. This buy mirrors a prior open-market purchase at OBIO on 2025-09-19, which delivered a +77.1% 90-day return. His cross-ticker buy history shows 1 prior buy with an avg 30d return of +35.5% and avg 90d return of +77.1%, with a 100.00% win rate on the 90-day mark. However, the stock is currently down -12.7% over the past 30 days and down -26.2% from its 52-week high of $5.42, suggesting the timing of this purchase relative to recent momentum warrants attention. The company remains unprofitable with net income of $-20.7M against revenue of $110.0K, though it recorded exceptional annual revenue growth of +1169.2%.

Director Fain Eric S bought 20,000 shares of OBIO at $4.13 on 2026-05-14; holding reaches 91.7K shares. Stock at $4.00, down -26.2% from 52-week high.

Director Fain Eric S purchased 20,000 shares at $4.13, increasing his stake from 71.7K to 91.7K shares (+27.9%). The transaction occurs with the stock trading at $4.00, substantially below its 52-week high of $5.42 and down -12.7% over the prior 30 days. His prior buy at this ticker on 2025-08-25 showed a 90-day return of +73.6%, which was well-timed. Additionally, 2 other insiders bought within the past 14 days, creating a cluster pattern of insider purchases. The company reported revenue of $110.0K in its latest quarter but net income of $-20.7M, with negative full-year profitability, setting this accumulation against a financially distressed backdrop.

Hochman bought 5,000 OBIO shares at $4.07 on 2025-11-14; stock up 24.4% in 30 days but insider's cross-ticker timing record weak.

Hochman David P purchased 5,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.07 on 2025-11-14, increasing his holdings to 612.8K shares. OBIO's stock has risen 24.4% over the prior 30 days and 62.0% over 90 days, recovering from a 52-week low of $2.35 toward a range floor following a -33.5% decline from the 52-week high of $6.21. However, Hochman's cross-ticker track record shows modest predictive value: 11 prior buys with an average 90-day return of -2.2% and a 90-day win rate of 10.00%, suggesting his timing has been poor in broader context. At the same ticker (OBIO), his prior trade history is mixed—only 1 of 4 prior buys showed positive 90-day returns, and he acquired shares as recently as 2025-08-21 at a loss. The underlying company remains unprofitable (net income $-20.8M in the latest period) despite the recent share-price appreciation, which warrants scrutiny of whether the rally is sustainable or momentum-driven.

Director Aryeh Jason buys 1,000 shares of OBIO at $2.45 as stock trades -61.6% from 52-week high.

Aryeh Jason, a director of Orchestra BioMed Holdings, purchased 1,000 shares at $2.45 on 2025-09-19, increasing his holdings from 107,482 to 108,482 shares. The transaction occurs in a context of significant distress: the company is unprofitable with a net loss of $-19.4M over the most recent full fiscal year, quarterly revenue has contracted year-over-year by 4.4%, and the stock is trading at $2.44, down 61.6% from its 52-week high of $6.36. The modest purchase size (1,000 shares, representing a 0.9% increase in his holdings) during a period of acute operational headwinds warrants monitoring but does not constitute material conviction evidence. The transaction is observable but requires context on whether this represents routine portfolio management or a broader pattern of board-level support during financial stress.

CFO Taylor Andrew Lawrence buys 2,000 shares of OBIO at $2.55; stock down -61.2% from 52-week high amid cluster buy activity

CFO Taylor Andrew Lawrence purchased 2,000 shares at $2.55 on 2025-08-25, adding to holdings that now total 482.8K shares. The transaction occurs as the stock trades -61.2% below its 52-week high of $6.70 and has declined -21.0% over the past 30 days. A cluster pattern is present: 3 other insiders also bought within the past 14 days. However, the company's fundamentals remain challenged—it posted a net loss of -$19.4M in the latest quarter and reported annual revenue growth of -4.4%, with the company unprofitable over its most recent full fiscal year. Lawrence's prior open-market buy at this ticker (2024-12-19) did not demonstrate well-timed execution (90d return -8.3%), which tempers the signal strength of the current purchase relative to broader price deterioration.

David P Hochman buys 6,000 OBIO shares at $2.49; stock down 61.2% from $6.70 high; 3 other insiders also bought in past 14 days.

Hochman purchased 6,000 shares at $2.49 on 2025-08-21, adding to holdings that now stand at 651.5K shares. The stock is currently trading at $2.60, down 61.2% from its 52-week high of $6.70 and down 21.0% over the past 30 days. Orchestra BioMed is unprofitable with a net income of $-19.4M on revenue of $836.0K (latest quarter), and annual revenue has contracted 4.4% year-over-year. Across his prior 4 measurable buys at this ticker, Hochman has not achieved a single positive 90-day outcome. A cluster pattern is evident: 3 other insiders also bought within the past 14 days. The transaction signals sustained insider acquisition activity despite deteriorating fundamentals and a stock down significantly from its 52-week peak, though prior purchase timing at this specific ticker has not proven predictive of near-term recovery.

Sherman Darren bought 3,000 shares of OBIO at $2.62; stock now $2.60, down 61.2% from 52-week high. Cluster pattern: 3 other insiders also bought in past 14 days.

Sherman Darren purchased 3,000 shares at $2.62 on 2025-08-25, increasing his holdings to 926,837 shares post-transaction. The stock has deteriorated significantly, trading at $2.60 (current price) versus a 52-week high of $6.70, representing a decline of 61.2% from peak. The company fundamentals are challenged: net income was $-19,363,000.00 over the most recent full fiscal year, and quarterly revenue stands at $836,000.00 with annual revenue growth of -4.4%. Notably, this purchase is part of a cluster pattern—3 other insiders also bought within the past 14 days—suggesting coordinated or synchronized accumulation at depressed levels. The convergence of multiple insider purchases amid material stock weakness and sustained unprofitability warrants attention to whether this reflects insider assessment of value or other factors driving the coordinated activity.

Director Fain Eric S bought 5,760 shares of OBIO at $2.61; 3 other insiders also bought in past 14 days

Eric S Fain, a director, purchased 5,760 shares at $2.61 on 2025-08-25, increasing his holdings by 8.7% to 71,709 shares. This purchase occurs as part of a cluster pattern, with 3 other insiders also buying within the past 14 days. The timing is notable given that the stock has declined -21.0% over the past 30 days and -61.2% from its 52-week high of $6.70. The company faces substantial headwinds: it reported negative net income of $-19,363,000.00 in its latest period, contracted -4.4% year-over-year in annual revenue, and generated only $836,000.00 in quarterly revenue against a $140.3M market cap. The coordinated insider buying activity against a backdrop of severe financial losses and recent sharp price declines is a factual pattern worth tracking.